Join Opthea, a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), for an in-person and virtual Investor Day in New York City.

As the Company prepares for the anticipated topline data readout of its two pivotal trials, COAST in early CY Q2 2025 and ShORe in mid-CY 2025, the event will feature presentations from international retina thought leader Charles C. Wykoff, MD, PhD and Opthea’s senior management team, including Chief Commercial Officer Mike Campbell.

Opthea’s Investor Day will highlight the following:

• The continued medical need for better vision outcomes in wet AMD and the opportunity for sozinibercept to transform patient lives with superior vision gains.
• New insights on the commercial potential and commercial readiness plans for sozinibercept in combination with standard-of-care anti-VEGF-A therapies.

A live question-and-answer session will follow the formal presentations.